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Background. CD133 is a member of a novel family of cell surface glycoproteins.
Initially, the expression of CD133 antigen was seen only in the hematopoietic
derived CD34+ stem cells. At present, CD133 expression is demonstrated in
undifferentiated epithelium, different types of tumors and myogenic cells.
CD133+ neurosphere cells isolated from brain are able to differentiate into
both neurons and glial cells. These data suggested that CD133 could be a
specific marker for various stem and progenitor cell populations.
Objectives. The main goal would be to describe the role for CD133 as a marker
of stem cells able to engraft and differentiate, to form functional non-
hematopoietic adult lineages and contribute to disease amelioration via
tissue regeneration.
Results/conclusion. In conclusion, since the rise of CD133 antigen as a suitable
stem cell marker, the possible use of CD133+ stem cells in therapeutic applica-
tions has opened a new promising field in the treatment of degenerating dis-
eases. The human circulating cells expressing the CD133 antigen behave as a
stem cell population capable of commitment to hematopoietic, endothelial
and myogenic lineages. CD133 cell therapy may represent a promising
treatment for many diseases.
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1. Introduction
In the last years, stem cells have received much attention for their potential use in
cell-based therapies for various human diseases; according to these observations, var-
ious stem cells were used to treat muscular dystrophy. CD133 is a member of a
novel family of cell surface glycoproteins [1-3] and it was recognized to be the homo-
logue of mouse prominin-1. Human prominin-1 is a transmembrane glycoprotein
of 865 amino acids with a total molecular mass of 120 kDa; it has a unique structure
consisting of an N-terminal extracellular domain, five transmembrane domains with
two large extracellular loops and a 59 aa cytoplasmic tail. Transcription of CD133 is
driven by five alternative promoters, three of which are located in a CpG island and
at least partially regulated by methylation [4]. The transcripts contain one of five
alternative 5¢-UTR first exons, which are expressed in a tissue-specific manner [4].
The function of CD133 is not known, and its ligand has not yet been identified.
At first, the expression of CD133 antigen was seen only in the hematopoietic
system-derived CD34+ stem cells, isolated from fetal liver, bone marrow and
peripheral blood [2,3]. These cells were successfully injected in animal models sug-
gesting that they had a long-term repopulating potential [3]. Later, CD133 expres-
sion was demonstrated on undifferentiated epithelium [5], retinoblastoma [2],
teratocarcinoma [2], leukemias [6,7], myogenic cells [8] and endothelial progenitors
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expressing VEGFR-2 and fetal brain neural stem cells [9]. In
particular, CD133 was best characterized for identifying nor-
mal brain stem cells [9] and tumor propagating cells (TPCs) in
brain tumors [10] and also used as a marker for colon cancer
TPCs [11]. In this context, an unusual relationship between
promoter DNA methylation and CD133 expression was
noted: further studies demonstrated a role for promoter meth-
ylation in the regulation of CD133 levels. Moreover CD133+
neurosphere cells differentiated into both neurons and glial
cells, and single CD133+ neurosphere cells were able to
re-establish neurosphere cultures, demonstrating the self-
renewal potential of this highly enriched population [12].
Increasingly, studies used CD133 as a marker to identify can-
cer stem cells from a variety of tumors (Figure 1E, 1F). How-
ever, Shmelkov’s recent work has raised serious concerns
over the use of CD133 as a general marker for cancer stem
cells. In this study [13], both CD133+ and CD133- metastatic
colon cancer cells EpCAM+ showed long-term tumorigenesis
in a NOD/SCID mouse model. This is different from what
was found in two previous studies in colon cancer [11,14]. Actu-
ally, there are no convincing explanations for this significant
controversy. Shmelkov et al. argued that the CD133- cells
used in the previous studies consisted of stromal cells, endo-
thelial cells but not tumorigenic cells of epithelial origin.
Another important issue is the variation in tissue sampling.
Even in the same type of cancer such as colon cancer, cells
are affected by the location where samples are taken (e.g., cen-
ter or periphery of a tumor), histopathological types, tumor
stages and treatments (drugs, irradiations). In fact, cancer
stem cell behavior is influenced by the surrounding
microenvironment (niche), which is affected by tumor sizes,
nutritional conditions, oxygen levels, chemotherapies and
irradiations [14-16]. Based on these controversial evidences, it
seems to be inappropriate to use CD133 as a general cancer
stem cell marker, particularly in tissues where CD133 is
expressed in epithelial cells and epithelial stem cells, and their
counterpart cancer cells and cancer stem cells.
These data suggested that CD133 could be a specific
marker for various stem and progenitor cell populations.
This review focuses on the possibility of using CD133+ stem
cells isolated from blood and muscle in cell-mediated thera-
pies in order to specify the clinical potentiality of this kind
of stem cells and their role in future clinical perspectives.
Moreover, the review describes a good number of clinical tri-
als demonstrating the applicability of these cells in different
fields rather than muscle pathologies.
2. CD133 as a stem cell marker
CD133 antigen is expressed by hematopoietic progenitors [3];
this evidence has directed interest towards the potential of
CD133 as a cell surface marker of adult stem cells. In hemato-
poietic lineages in humans, CD133 antigen expression is
restricted to CD34+ cells, although CD133 transcripts have
been found inmany human cell lines and differentiated cells [18].
A role for CD133 as a marker of stem cells with the capacity to
engraft and differentiate to form functional non-hematopoietic
adult lineages and contribute to disease amelioration via
tissue regeneration is emerging, and CD133+ cell therapy may
represent a promising treatment for many diseases. Human
CD133+ cells, isolated from human peripheral blood and
manipulated in vitro to undergo myogenesis, were shown to
ameliorate disease via a direct contribution to muscular regener-
ation when transplanted into scid/mdx dystrophic mice, a model
of Duchenne muscular dystrophy (DMD) [8]. DMD, the most
common formofmuscular dystrophy, is anX-linked genetic dis-
order due to either spontaneousmutations or inherited nonsense
point mutations in the dystrophin gene [19]. Dystrophin is
responsible for the maintenance of cell integrity and muscle
cell function [20]. The loss of a functional dystrophin protein
gives rise to progressive muscle degeneration in DMD patients
as a result of mechanical stress during contraction that leads to
death in the second second/third decade of the patient’s
life [21]. Human circulating CD133+ cells were also induced to
undergo either endothelial or cardiomyocytic differentiation
in vitro [8]. In addition to the hematopoietic system, CD133 is
also expressed on endothelial progenitor cells (EPCs), which
play a role in angiogenesis and neovasculogenesis during both
tumor growth and wound healing [23]. In a clinical point of
view, CD133+ stem cells are to migrate into the vasculature. In
2006, we discovered the mechanisms involved in the muscle
homing of CD133+ stem cells, allowing the systemic delivery
of such stem cells. Almost all CD133+ cells co-expressed
CD44 and LFA-1, while > 40% of the CD133 cells expressed
PSGL-1, VLA-4, L-selectin and CCR7. The expression of this
pattern of adhesion molecules gave to CD133+ stem cells the
potentiality to mediate the migration through the blood vessel
wall.We also showed the expression ofmurine endothelial adhe-
sion molecules potentially involved in dystrophic muscle hom-
ing, such as ICAM-1, VCAM-1, P-selectin and E-selectin [23].
As all these studies were carried out in the frame of a more gen-
eral research program aiming to use human stem cells to repair
muscle damage in muscular dystrophies, such as DMD, it was
clear that the elucidation of the mechanisms involved in muscle
homing of stem cells could aid in improving a potential therapy
for those diseases. In this sense, combining nanoparticle labeling
of blood-derived CD133+ cells and the X-ray computed micro-
tomography, we provided detailed information on the stem
cell migration in 3D. This is of special importance if the
cells are administered systemically rather than directly into the
target tissue. Intra-arterially administered labeled CD133+
stem cells were distributed around the vessels of muscle tissues.
It is very important in the future to combine cell therapy and
innovative technology in order to study the distribution of the
injected cells.
3. Blood derived CD133+ cells
In the paper published in 2004, we obtained the first evidence
that CD133+ cells isolated from peripheral blood exhibited
CD133+ cells isolated from various sources and their role in future clinical perspectives
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stem cell behavior (Figure 1A) [8]. The cloned CD133-derived
stem cells were able to commit to more than one lineage, such
as hematopoietic and endothelial. In particular, we demon-
strated that circulating CD133+ cells were able to differentiate
into myotubes in vitro and to participate in skeletal muscle
regeneration in a murine model of DMD, the scid/mdx
mouse, expressing several myogenic markers such as MYF5,
m-cadherin and Pax7. Moreover, when these cells were cul-
tured in the presence of a feeder layer of mouse myogenic
cells, they fused and formed myosin heavy chain (MyHC)-
expressing heterozygous-specific human/murine myotubes
(Figure 1B) [8]. Following the in vitro characterization, we
assessed the in vivo behavior of CD133+ stem cells isolated
from blood in term of capacity to restore dystrophin expres-
sion and eventually regenerate the satellite cells pool in scid/
mdx mouse after intramuscular and intra-arterial delivery.
Human CD133+ cells colonized the mouse muscle and
formed hybrid regenerated fibers expressing human dystro-
phin. When transplanted into dystrophic skeletal muscle,
human cells differentiated into satellite cells; in fact, they
were located beneath the basal lamina and distributed along
freshly isolated fibers, co-expressing m-cadherin. After intra-
arterial injections, CD133+ donor cells were detected in sev-
eral vessels near areas of regeneration, where they expressed
human ve-cadherin and CD31 [8]. According to these
evidences, we suggested that human blood-derived CD133+
cells migrated within muscle tissues and differentiated into
endothelial, satellite cells and human dystrophin-positive
muscle fibers. Moreover, we noted a significative recovery of
force after treatment with a value similar to the normal
mice [8].
Other researchers demonstrated that autologous CD133+
bone marrow-derived cells induced angiogenesis and restored
myocardial tissue viability after infarction, as discussed in
detail below [25,26].
4. Muscle derived CD133+ cells
As we isolated myogenic CD133+ from blood, we assessed to
identify a similar population from muscle (Figure 1C). We
identified a subpopulation of stem cells expressing the
CD133 together with CD34, CD45 and KDR from human
normal and DMD biopsies. Muscle-derived CD133+ cells
were present in both normal and DMD muscles, although
dystrophic muscle biopsies of young patients (5 -- 14 years
old) contained a higher number of these cells than muscle
biopsies of healthy donors matched for age [27]. They repre-
sented 2% of the total dystrophic muscle-derived nucleated
cells. Both normal and dystrophic muscle-derived CD133+
cells expressed the CD45 antigen (4%), indicating their
A. B.
C. D.
Figure 1. CD133+ cells isolated from peripheral blood in proliferation medium A.; blood derived CD133+ cultured in the
presence of a feeder layer of murine myotubes fused (human nuclei stained with lamin A/C antibody in red) and formed
MyHC-expressing heterozygous-specific human/murine myotubes (green) B.; muscle-derived CD133+ cells in culture C.; in
the proliferation medium, muscle derived CD133+ cells were to differentiate into multinucleated myotubes expressing
MyHCs (green) D.
MyHC: Myosin heavy chain.
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hematopoietic commitment [27]. Furthermore, the expression
of Pax-7, Myf-5, MyoD, m-cadherin, MRF-4 and myogenin
after 24 days of culture in the proliferation medium and their
ability to differentiate into multinucleated myotubes express-
ing MyHCs suggested a myogenic commitment (Figure 1D).
As we assessed the capacity of proliferation and differentiation
of CD133+ stem cells isolated from normal and dystro-
phic muscle biopsies, we decided to consider the muscle-
derived CD133+ cells as a class of myogenic precursors. In a
clinical point of view, we investigated their safety after
transplantation in DMD muscles [26].
Our data showed that intramuscular transplantation of
muscle-derived CD133+ cells in DMD patients was a safe
procedure and feasible [26]. Following the injection of
CD133+ stem cells, the patients showed an increased number
of capillaries per muscle fiber and expressed a change in the
ratio of slow:fast myosin myofibers.
5. Therapeutic applications of CD133+ cells
Since the rise of CD133 antigen as a suitable stem cell marker,
the possible use of CD133+ stem cells in therapeutic applica-
tions opened a new promising field in the treatment of degen-
erating diseases. Bhatia et al. demonstrated that transplanted
CD133+ CD34- cells resulted in similar repopulating poten-
tials as CD34+ cells and can differentiate into CD133+
CD34+ cells with hematopoietic and endothelial capacity [27].
Following hematopoietic stem cell transplantation, early clin-
ical studies showed slightly improved engraftments with
CD133+ cells compared to CD34+ cells [29]. In addition, as
described above, our results demonstrated that circulating
CD133+ cells differentiated in myogenic cells and might be
used for stem cell therapy of muscular dystrophy [8].
Stamm et al. showed that transplanted bone marrow-
derived CD133+ cells improved function of infracted myocar-
dium probably as a result of the amelioration in blood vessel
formation [29]. Despite these considerations, the isolation of
CD133+ stem cells provided a selective population useful for
transplantation and tissue regeneration as well as targeting
population of malignantly transformed stem cells in certain
cancers [8,26]. We extended these observations to a combina-
tion of cell- and gene-based approaches via the ex vivo intro-
duction of corrective genes into dystrophic CD133+
myogenic cells which would permit their subsequent autolo-
gous transplantation. Use of the patient’s own cells would
reduce the risk of implant rejection. As a correction method,
we used the exon skipping approach. This technology uses
specific antisense oligonucleotides designed to mask the puta-
tive splicing sites of exons in the mutated region of the pri-
mary RNA transcript whose removal would re-establish a
correct reading frame. The D49 -- 50 DMD deletion was cho-
sen to test the capacity of the exon-skipping strategy to restore
open reading frame to the dystrophin mRNA sequence in
CD133+ stem cells [30]. Theoretically, skipping of exon
51 in this context should eliminate the original frameshift,
revealing a correct reading frame between exons 48 and 52.
Both stem cell populations were transduced with a lentiviral
vector expressing the U7 snRNA containing antisense sequen-
ces designed specifically to skip exon 51 and able to restore
open reading frame to a range of DMD genotypes. In accor-
dance with our hypothesis, the genetically engineered DMD
stem cells expressed a shortened dystrophin mRNA specifi-
cally deleted for the exon 51 [30]. Our results also showed
that human genetically engineered DMD blood and muscle-
derived CD133+ can become located beneath the basal lamina
and distributed along freshly isolated fibers where they express
M-cadherin: all are indications that they can differentiate into
satellite cells within the recipient dystrophic skeletal mus-
cle [30]. However, intramuscular transplantations lead only
to local and focused regeneration whereas DMD pathology
affects the whole body musculature and its effective treatment
requires methods to distribute the injected cells to these dis-
persed sites. This problem might be circumvented by intra-
arterial injection as a means of obtaining more dispersed
delivery of CD133+ stem cells into dystrophic individuals.
Another important question that emerged with the
CD133+ cells injection -- unfortunately, common to a lot of
different types of stem cells -- is the self-renewal potential of
the CD133+ transplanted cells. Although it is known that
these cells are able to differentiate in vitro and participate to
ameliorate the dystrophic phenotype of animal model after
their transplantation [8,26,30], it is not clearly known how
long CD133+ isolated from muscle and blood can contribute
to host tissue regeneration. However, it was previously pub-
lished that CD133+ cells were able to exhibit myogenic prop-
erties 60 days [30] after transplantation in scid/mdx mice.
Moreover, it could be very important to determine how
many times cellular transplantation is performed to have bet-
ter results in terms of efficiency of muscular development.
Various studies are now in progress trying to find answers to
these important questions, above all for a possible future
therapeutic application of CD133+ stem cells.
Ongoing Phase I/II studies try to assess the efficacy and the
safety of the injection of CD133+ stem cells isolated from dif-
ferent tissues applying to human diseases such as ischemia,
refractory coronary heart disease, cirrhosis and myocardial
infarction. In case of ischemia, the primary objective is to ana-
lyze the safety and efficacy of CD133+ cells obtained from
peripheral blood in the treatment of diabetic patients with
critic ischemia in lower limbs. The secondary objectives are:
to determine the safety of the intramuscular administration
of CD133+ cells that have been mobilized from peripheral
blood, to determine the CD133+ capacity to increase the re-
vascularization at lower limbs in diabetic patients with critic
ischemia in the lower limbs and to evaluate the patient’s
global health. The majority of studies tries to assess the
efficacy of an autologous transplantation of CD133+ in heart
pathologies; one of these studies evaluates if the intra-
coronary infusion of autologous bone-marrow derived
CD133+ endothelial precursor cells is able to promote
CD133+ cells isolated from various sources and their role in future clinical perspectives
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neo-vascularization and improve myocardial perfusion and
contractility in patients with refractory coronary heart disease,
characterized by a poor response to standard coronary inter-
ventions, severe impairment of the quality of life and a poor
prognosis. A completed study demonstrated the safety of
intracoronary injection of CD133+ cells from autologous
bone marrow (ABM) and mobilized peripheral blood
(MPB) in the target population and the efficacy, selective
injection of CD133+ cells from ABM and MPB in the culprit
vessel of the target population, and regional and global con-
tractile function and perfusion and metabolism of the
infarcted area. Limsuwan et al. published that a young patient
suffering from myocardial infarction was transplanted with
bone marrow-derived CD133+ CD34+ cells, showing
improvement in functional capacity [25]. Although the amelio-
ration of myocardium could be in part due to the daily injec-
tion of G-CSF, this condition is probably the consequence of
the ability of injected cells to contribute to cardiac repair in
terms of induction of angiogenesis, inhibition of apoptosis
and promotion of myocite recovery.
In another work, Flores-Ramirez et al. demonstrated that a
single coronary infusion of CD133+ EPCs into the infracted
area improved heart function for 2 years after the treatment
and remarkably improved the quality of life in treated
patients [31]. Moreover, the intracoronary infusion of these
cells seemed to be a minimally invasive, safe and less expansive
method of treating patients with limited therapeutic options.
Unfortunately, this study was limited by the small numbers
of patients and the lack of control subjects. In addition,
Navarro-Sobrino et al. showed that patients suffering from
stroke mobilized an EPC fraction (CD133+ CD34+ KDR+
CD45+) characterized by a great capacity to induce vasculo-
genesis and secrete angiogenic factors [32]. Now, fifteen ongo-
ing Phase I and II studies are started using CD133+ stem cells
(www.clinicaltrials.gov).
Although blood and muscle-derived CD133+ cells are
largely used in different fields to regenerate pathological tis-
sues, several things need to be ameliorated to consider these
cells suitable for cellular therapy. We need to enhance the
rate of proliferation of blood-derived CD133+ cells in culture
and their storage for repeated treatments. We have to under-
stand why blood-derived CD133+ cells are less efficient com-
pared with muscle-derived CD133+ cells in terms of
contribution of muscle nuclei. At the end, we have to amelio-
rate the strategy to deliver myogenic cells chronically to the
various sites of sporadic regeneration that occur in
muscular dystrophies.
6. Heterogeneity of CD133+ stem cells
Extraordinary progress in the understanding of several key
features of stem cells has been made in the last 10 years,
including definition of the niche, identification of signals
regulating mobilization and homing as well as partial
understanding of the mechanisms controlling self-renewal
commitment and differentiation [33]. This progress has pro-
duced invaluable tools for the development of rational cell
therapy protocols that have yielded positive results in preclin-
ical models of genetic [34] and acquired diseases and, in several
cases, have entered clinical experimentation with a positive
outcome [35].
The research is an important step towards understanding
stem cell behavior, how cellular development is controlled,
and how a single cell -- which has the genetic code within it
to become any cell in the body -- is told what to become,
where to go and what metabolic function to perform.
A major limitation in these studies is the heterogeneity of
stem cell populations obtainable by commercialized stem cells
isolation methods [36]. The recruitment to myogenesis of res-
ident and circulating progenitors can be strongly enhanced,
being central in the support of muscular tissue functionality.
CD133+ cells have been characterized for their regenerative
potential in vivo as well as their ability to repopulate the satel-
lite cell niche and they could be stratified for the expression of
CD34 antigen identifying a subpopulation displaying high
myogenic potential in vitro and in vivo. Probably, CD133+
cells represent a heterogeneous population which includes a
common progenitor with round shape, low proliferative
capacity and potential to give rise to myogenic, endothelial
and pericyte cells. Negroni et al. demonstrated that more
human mononuclear cells remained in the interstitial space
in the muscle injected with CD133+/CD34+ cells when com-
pared with the human myoblasts [37]. The percentage of
undifferentiated interstitial cells confirms that all CD133+
stem cells are not at the same stage of myogenic commitment
and that some of the cells never go to terminal differentia-
tion [37]. These evidences confirm that CD133+ cells are a het-
erogeneous population and contain a fraction already
committed to myogenic differentiation giving rise to myonu-
clei and satellite cells and a fraction with slower capacity to
differentiate improving regeneration by secreting factors that
stimulate the amelioration of the muscle regeneration when
injected in a dystrophic behavior [37].
CD133+ cells and mesoangioblasts can display similar
behaviors in experimental conditions: mesoangioblasts [38]
and CD133+ cells [23] have the ability to migrate through
the vasculature rendering these cells good candidates for cell
therapy. These evidences suggest that there is a probable
connection between the origin and the development of
these two kinds of progenitor cells. Such an event repre-
sents a clear explanation of the quantitative incongruence
highlighted by the work of Grounds and McGeachie, demon-
strating that the number of resident satellite cells is much
smaller that the number of committed myogenic precursors
that populate the muscle tissue soon after injury [39]. More-
over, it is unclear why all these progenitor cells are not able
to defeat or at least ameliorate the symptoms of the disease.
We propose that these committed progenitors were the steps
of differentiation of a common un-differentiated stem cell
whose function is largely unknown.
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7. Expert opinion
Stem cell therapy is an attractive method to treat human
pathologies because only a small number of cells, together
with a stimulatory signal for expansion, are required to obtain
a therapeutic effect [40]. Different ongoing and concluded
clinical trials demonstrated the applicability of CD133+
stem cells particularly in the treatment of ischemia, refractory
coronary heart disease, cirrhosis and myocardial infarction.
Recently, promising results were published showing improve-
ment in functional capacity in case of treatment of patients
affected by heart pathologies [25,31]. In particular, we studied
the clinical potential of these cells isolated from blood and
muscle in the treatment of muscular dystrophy [8,30]. We
know that the clinical relevance candidate stem cell popula-
tion must be easily extracted, must remain capable of efficient
myogenic conversion and when transplanted must integrate
into the muscles allowing the functional correction of the dys-
trophic phenotype [40]. Survival and the migration from the
site of injection to the compromised muscles of the body
remain suboptimal for many of the cell populations. We dem-
onstrated that human circulating cells expressing the
CD133 antigen behave as a stem cell population capable of
commitment to hematopoietic, endothelial and myogenic lin-
eages and the discovery of the mechanisms involved in the
muscle homing of stem cells improved a potential therapy
for muscular dystrophy based on the systemic delivery of
this population of stem cells [23].
CD133+ cells seem to satisfy the most criteria for use in
the treatment of muscular dystrophy. Nevertheless, several
issues have to be clarified such as the time required in culture
for autologous cells before re-implantation into the patients
and the contribution to muscle nuclei of blood- and muscle-
derived CD133+ cells and the time that these cells engraft
the satellite cell compartment, allowing the formation of
genetically corrected stem cells into the muscle. Although
satellite cells remain the primary cells responsible for the
regeneration of post-natal skeletal muscle, several other cell
types, such as MDSCs, CD133+ cells and mesoangioblasts,
can display similar behavior in experimental conditions. As
we explained before, it is very important to clarify the possi-
bly common origin of these stem cell populations, their rela-
tionship to satellite cells and whether these myogenic cells
have the potential to give rise to muscular cell lineages also
in steady-state conditions [41]. It is expected that a robust
and thoroughly tested model of gene networks involved in
stemness will be instrumental in the identification of a novel
stem cell isolation method able to produce a ‘pure’ stem cell
population. We strongly believe that combining mathemat-
ical modeling with computational and experimental
approaches will efficiently tackle this problem, thus, bring-
ing a holistic understanding of the molecular mechanisms
that maintain stem cells in an undifferentiated state or on
the contrary result in their engagement into a specific
differentiation pathway. Understanding what defines stem-
cellness may have a profound impact also in understanding
the role of circulating rare stem cells in normal or patholog-
ical conditions. For the large economical burden that they
represent, it is critical to develop innovative approaches
and to explore novel avenues of research that will be instru-
mental in discovering new biomarkers and cures for cancer
pathologies and other diseases such as hematopoietic and
muscle wasting.
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